These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 9284737

  • 1. Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors.
    Marsh DJ, Zheng Z, Arnold A, Andrew SD, Learoyd D, Frilling A, Komminoth P, Neumann HP, Ponder BA, Rollins BJ, Shapiro GI, Robinson BG, Mulligan LM, Eng C.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3025-8. PubMed ID: 9284737
    [Abstract] [Full Text] [Related]

  • 2. Infrequent detectable somatic mutations of the RET and glial cell line-derived neurotrophic factor (GDNF) genes in human pituitary adenomas.
    Yoshimoto K, Tanaka C, Moritani M, Shimizu E, Yamaoka T, Yamada S, Sano T, Itakura M.
    Endocr J; 1999 Feb; 46(1):199-207. PubMed ID: 10426588
    [Abstract] [Full Text] [Related]

  • 3. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ, Mulligan LM, Eng C.
    Horm Res; 1997 Feb; 47(4-6):168-78. PubMed ID: 9167949
    [Abstract] [Full Text] [Related]

  • 4. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G, Yu Y, Jing S, Vecchio G, Fusco A, Santoro M.
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [Abstract] [Full Text] [Related]

  • 5. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P.
    Verh Dtsch Ges Pathol; 1995 Aug; 79():L-LV. PubMed ID: 8600671
    [Abstract] [Full Text] [Related]

  • 6. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
    Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M.
    Hum Mutat; 1999 Aug; 13(4):331-6. PubMed ID: 10220148
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
    Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, Goltzman D, Hendy GN.
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
    Eng C, Mulligan LM.
    Hum Mutat; 1997 Jul; 9(2):97-109. PubMed ID: 9067749
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E, Russo D, Giuffrida D, Zampa GA, Meringolo D, Arturi F, Chiodini I, Bianchi D, Attard M, Trischitta V, Bruno R, Giannasio P, Pontecorvi A, Filetti S.
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [Abstract] [Full Text] [Related]

  • 16. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M, Weinhüsel A, Niederle B, Haas OA.
    Int J Cancer; 1996 Aug 22; 69(4):312-6. PubMed ID: 8797874
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
    Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF.
    Rev Med Chil; 2001 Jul 22; 129(7):713-8. PubMed ID: 11552438
    [Abstract] [Full Text] [Related]

  • 20. Expression of RET and its ligand complexes, GDNF/GFRalpha-1 and NTN/GFRalpha-2, in medullary thyroid carcinomas.
    Frisk T, Farnebo F, Zedenius J, Grimelius L, Höög A, Wallin G, Larsson C.
    Eur J Endocrinol; 2000 Jun 22; 142(6):643-9. PubMed ID: 10822229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.